Arbor Pharmaceuticals has completed its acquisition of XenoPort for $467m.

Arbor Pharmaceuticals, a pharmaceutical company, has completed its acquisition of XenoPort, a biopharmaceutical company for $467m. “We are pleased to be adding HORIZANT and the XenoPort pipeline to the growing portfolio of Arbor products. We believe that XenoPort’s lead product HORIZANT offers patients and physicians a valuable treatment option for moderate-to-severe primary restless legs syndrome and postherpetic neuralgia. The XenoPort sales team has done an excellent job of growing HORIZANT, and we look forward to supporting them to continue this significant momentum.” Ed Schutter, Arbor President and Chief Executive Officer.